Dolphin Medical Services Limited has informed the Bombay Stock Exchange of an upcoming Board of Directors meeting scheduled for May 16, 2026. The meeting will be held at the company's registered office located at Level 3, Plot No. 13, Greenlands Colony, Besides Flyover Gachibowli, Gachibowli, K.V. Rangareddy, Seri Lingampally, Telangana, India – 500032. The intimation was issued on May 11, 2026, in compliance with applicable regulatory requirements.

Board Meeting Details

The board meeting has been convened pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda of the meeting is to consider and approve the audited financial results for the fourth quarter and the financial year ended March 31, 2026.

Key details of the scheduled board meeting are summarised below:

Regulatory Compliance

The filing was made to the Department of Corporate Services, Bombay Stock Exchange Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. The disclosure underscores the company's adherence to its listing obligations under SEBI regulations. The intimation was duly signed by Dr. Mohan Prasad GV, Managing Director (DIN: 01236113), on behalf of Dolphin Medical Services Limited.

Dolphin Medical Services Limited announced significant changes to its board composition following a board meeting held on April 22, 2026. The meeting, which commenced at 08:30 PM and concluded at 09:20 PM IST, resulted in the appointment of two new independent directors and the acceptance of three director resignations, all effective immediately. The changes were disclosed pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

New Independent Director Appointments

The board approved the appointment of two independent directors based on recommendations from the Nomination and Remuneration Committee. Both appointments are for five-year terms and comply with provisions under Sections 149(6), 150, and 152 of the Companies Act, 2013, subject to shareholder approval.

Mr. Kolachalama Saikumar is a Chartered Accountant with over 10 years of expertise in audit, specializing in ASM audits, statutory audits, and concurrent audits of public and private sector banks. He is certified in Valuation and DISA (ICAI) with strong understanding of regulatory compliance, internal control assessments, and risk management frameworks. He is skilled in conducting detailed audit reviews under RBI guidelines.

Smt. Srujana Siddhani is an experienced Senior Consultant Obstetrician & Gynecologist, Laparoscopic Surgeon, and Infertility Specialist with over 19 years of experience. She is recognized as one of the best gynecologists and specializes in female reproductive organs care with advanced treatments that help patients recover quickly and safely.

Director Resignations

The board accepted resignations from three directors, all effective April 22, 2026. Each resigning director cited professional unavoidable circumstances as the primary reason for their departure.

All three departing directors confirmed that there are no material reasons for their resignations other than professional commitments. The board placed on record its appreciation for their contributions during their respective tenures.

Regulatory Compliance

Both newly appointed independent directors confirmed they are not debarred from holding director positions by any SEBI order or other authority, in accordance with BSE circular dated June 20, 2018. Neither appointee is related to any existing directors of the company as defined under Section 2(77) of the Companies Act, 2013. The company has filed the necessary information with the Bombay Stock Exchange and will complete required formalities with the Registrar of Companies. The resigning directors held no directorships in other listed entities.